Frequently asked questions | Leukaemia Foundation

Frequently asked questions

Here you’ll find answers to our most commonly FAQs, as well as additional information about the services the Leukaemia Foundation offers.

Blood cancer facts and statistics

How many people are diagnosed with blood cancer every year?

Every year, more than 15,000 Australians will be newly diagnosed with blood cancer such as leukaemia, lymphoma and myeloma. This is equivalent to 41 people every day or one person every 36 minutes.

Is the incidence of blood cancer increasing?

Yes, the incidence of blood cancer continues to grow. Over the past 10 years, the incidence of blood cancer has increased by approximately 30% (i).

How many people in Australia have blood cancer?

More than 110,000 people are living with a blood cancer or a related blood disorder in Australia today.

Is blood cancer common?
Blood cancer is one of the most commonly diagnosed cancers in Australia. When combined, blood cancers are among the most frequently diagnosed cancers in the Australian community, and the most significant cause of non-preventable cancer death.

What’s the most common blood cancer?

Lymphoma is the most commonly diagnosed blood cancer in Australia, and the sixth most common form of cancer (ii).

How many people in Australia lose their lives to blood cancer?

Blood cancer is one of the highest causes of cancer death in Australia, claiming more lives than breast cancer (3,090, (iii) ) and melanoma (1,725) combined (iv). Up to 7,500 people in Australia are expected to lose their life to blood cancer or related blood disorders in 2020. This is equivalent to up to 20 people per day in Australia.

How common is blood cancer in children?

Blood cancer (specifically, leukaemia and lymphoma) remains the most commonly diagnosed childhood cancer (for those aged 0-14 years) in Australia, accounting for approximately 30% of all diagnoses (v).

Blood cancer basics

What is leukaemia?

Leukaemia is the general name given to a group of cancers that develop in the bone marrow. More information about leukaemia can be found here.

What is lymphoma?

Lymphoma is the general term for cancers that develop in the lymphatic system. More information about lymphoma can be found here.

What is blood cancer?

Blood cancer is a term that refers to cancers affecting the blood, bone marrow, and lymphatic system. Leukaemia, lymphoma, and myeloma are all blood cancers.

What’s the difference between non-Hodgkin lymphoma and Hodgkin lymphoma?

There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from all other types of lymphoma because of the presence, under the microscope, of a special kind of cancer cell called a Reed-Sternberg cell. The World Health Organisation currently recognises 43 sub-types of lymphoma. Five of these sub-types belong to a group of diseases called Hodgkin Lymphoma. All other sub-types are commonly grouped together and called non-Hodgkin Lymphomas.

What is MDS?
MDS is short for Myelodysplastic syndromes (myelodysplasia). This a group of diseases which affect the production of normal blood cells in the bone marrow. Find out more about MDS here.

What is ALL?

ALL is short for acute lymphoblastic leukaemia, a type of blood cancer. There are a few different types of ALL – find out more here.


What’s a stem cell transplant?

Bone marrow and blood stem cell transplantation (commonly referred to as simply stem cell transplantation) is used to treat a range of diseases. In short, a stem cell transplant is necessary to ensure that the bone marrow is repopulated with healthy blood stem cells following high-dose treatment. The new blood stem cells will rebuild your body’s blood and immune systems. You can find more information about stem cell transplants here.

What’s a clinical trial?

A clinical trial is a research study that helps to determine whether a new drug or device is safe and effective. Each study is designed to answer questions and find better ways to screen, diagnose, prevent or treat a disease or condition. There’s more information about clinical trials here.

About the Leukaemia Foundation

What is the Leukaemia Foundation?
The Leukaemia Foundation is the only national charity dedicated to helping those with leukaemia, lymphoma, myeloma and related blood disorders survive and then live a better quality of life. Learn more about the work we do and how we support people living with blood cancer.

Where is the Leukaemia Foundation?

We have offices across Australia, with our head office located in Brisbane. For a full list of our accommodation centres, support offices, and administrative offices, click here.

What blood cancers and disorders does the Leukaemia Foundation offer services and support for?
The Leukaemia Foundation supports everyone with a blood cancer and related blood disorder. This list acknowledges some of the more prevalent blood cancers that our teams work with every day. Even if your diagnosis is not on this list, we’re here to help.


  • Acute myeloid leukaemia (AML)​, Acute myelomonocytic leukaemia (AMML)​, Acute lymphoblastic leukaemia (ALL)​, Acute promyelocytic leukaemia (APML)​, Chronic myeloid leukaemia (CML)​, Chronic lymphocytic leukaemia (CLL)​, Richters syndrome​, Hairy cell leukaemia, Biphenotypic leukaemia​, Myeloid sarcoma (localised leukaemia)​.

Lymphoma (60+ sub-types, most common are listed):

  • Non-Hodgkin lymphoma​ B-Cell:​ Follicular​, Diffuse large B-cell (DLBCL), Burkitt’s, Mantle cell​, Primary mediastinal B-cell (PMBCL)​, Primary cutaneous B-cell​, Small lymphocytic (SLL)​, Marginal zone​, MALT, Lymphoplasmacytic / Waldenstrom’s macroglobulinaemia (WM), Double hit (DHL).
  • T-Cell / NK-Cell:​ Adult T-Cell leukaemic (ATLL)​, Anaplastic large cell (ALCL)​, Peripheral T-Cell , Cutaneous T-Cell​, Mycosis fungoides​, Śezary syndrome​, Subcutaneous panniculitis-like T-Cell ​, T-Lymphoblastic, Hodgkin lymphoma​, Nodular sclerosing HL, Mixed cellularity HL, Lymphocyte depleted HL, Lymphocyte rich HL, Nodular lymphocyte predominant HL​.

Blood disorders

  • Aplastic anaemia (AA)​, Systemic mastocytosis, Paroxismal nocturnal haemoglobinuria​.
  • Amyloidosis​: AA – secondary amyloidosis, AL – systemic amyloidosis, ATTR – familial amyloidotic polyneuropathy, ATTR – wild type – senile amyloidosis, Afib – mutated fibrinogen alpha chain​.


  • Smouldering / indolent myeloma​, IgG myeloma​, IgA myeloma​, Light chain myeloma​, Monoclonal gammopathy of unknown significance (MGUS)​, Multiple myeloma​, Plasmacytoma (localised myeloma)​, Osteosclerotic myeloma​.

Myeloproliferative neoplasms

  • ​Essential thrombocythaemia (ET), Polycythaemia (Rubra) vera (PV)​, Myelofibrosis (MF)​, Chronic myelomonocytic leukaemia (CMML), Juvenile myelomonocytic leukaemia (JMML)​, Chronic neutrophilic leukaemia (CNL), Chronic eosinophilic leukaemia (CEL), Systemic mastocytosis (SM)
  • Myelodysplasia​: Myelodysplastic syndrome (MDS)​, Refractory anaemia (RA), Myelodysplastic syndrome with del (5q) chromosome, Refractory anaemia with ringed sideroblasts (RARS), Refractory anaemia with excess blasts – type 1 (RAEB -1), Refractory anaemia with excess blasts – type 2 (RAEM-2), Refractory cytopenia with multilineage dysphasia (RCMD), Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMDRS)​.



Last updated on March 2nd, 2020

Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.

Share this page